Trial · NCT01005602
Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care
NCT01005602, Phase 4, Completed, University of Illinois Chicago; results first posted 2014-05-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care. Trials, record NCT01005602. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01005602
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care
- NCT number
- NCT01005602
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 131 participants, actual
- Lead sponsor
- University of Illinois Chicago
- Conditions
- Heart Failure
- Interventions
- Digoxin Dosing per Nomogram, Digoxin
- First posted
- 2009-11-02
- Last updated
- 2014-05-22
- Results first posted
- 2014-05-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml | Steady-state (2 - 4 weeks after initiation) | |
| Secondary | Mean Serum Digoxin Concentration | Steady-state (2 - 4 weeks after initiation) | |
| Secondary | Serum Digoxin Concentration < 1.0 ng/ml | Steady-state (2 - 4 weeks after initiation) | |
| Secondary | Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T | Steady-state (2 - 4 weeks after initiation) | 55 patients in the Digoxin Dosing per Nomogram group consented to the Pharmacogenetic substudy and provided blood samples to perform pharmacogenetic analyses. We compared serum digoxin concentrations by ABCB1 genotype. |
| Secondary | Serum Digoxin Concentration by ABCB1 SNP C3435T | Steady-state (2 - 4 weeks after initiation) | Serum digoxin concentration by genotypes for the ABCB1 SNP C3435T |
| Secondary | Serum Digoxin Concentration by ABCB1 SNP G2677T/A | Steady-state (2 - 4 weeks after initiation) | Serum digoxin concentration by ABCB1 SNP genotypes |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml | Steady-state (2 - 4 weeks after initiation) | percentage of participants | NUMBER | |
| SECONDARY | Mean Serum Digoxin Concentration | Steady-state (2 - 4 weeks after initiation) | ng/ml | MEAN | |
| SECONDARY | Serum Digoxin Concentration < 1.0 ng/ml | Steady-state (2 - 4 weeks after initiation) | percentage of participants | NUMBER | |
| SECONDARY | Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T | Steady-state (2 - 4 weeks after initiation) | ng/ml | MEAN | |
| SECONDARY | Serum Digoxin Concentration by ABCB1 SNP C3435T | Steady-state (2 - 4 weeks after initiation) | ng/ml | MEAN | |
| SECONDARY | Serum Digoxin Concentration by ABCB1 SNP G2677T/A | Steady-state (2 - 4 weeks after initiation) | ng/ml | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml | Digoxin Dosing Per Nomogram | 38.5 | percentage of participants | ||
| Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml | Standard Digoxin Dosing | 34.8 | percentage of participants | ||
| Mean Serum Digoxin Concentration | Digoxin Dosing Per Nomogram | 0.52 | Standard Deviation 0.30 | ng/ml | |
| Mean Serum Digoxin Concentration | Standard Digoxin Dosing | 1.12 | Standard Deviation 0.58 | ng/ml | |
| Serum Digoxin Concentration < 1.0 ng/ml | Digoxin Dosing Per Nomogram | 86.2 | percentage of participants | ||
| Serum Digoxin Concentration < 1.0 ng/ml | Standard Digoxin Dosing | 42.4 | percentage of participants | ||
| Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T | Wild Type | 0.52 | Standard Deviation 0.27 | ng/ml | |
| Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T | CT Genotype | 0.56 | Standard Deviation 0.37 | ng/ml | |
| Serum Digoxin Concentration by ABCB1 Single Nucleotide Polymorphism (SNP) C1236T | TT Genotype | 0.58 | Standard Deviation 0.29 | ng/ml | |
| Serum Digoxin Concentration by ABCB1 SNP C3435T | Wild Type (CC) | 0.54 | Standard Deviation 0.28 | ng/ml |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Digoxin Dosing Per Nomogram | 66 | |
| Overall Study | STARTED | Standard Digoxin Dosing | 66 | |
| Overall Study | COMPLETED | Digoxin Dosing Per Nomogram | 65 | |
| Overall Study | COMPLETED | Standard Digoxin Dosing | 66 | |
| Overall Study | NOT COMPLETED | Digoxin Dosing Per Nomogram | 1 | |
| Overall Study | NOT COMPLETED | Standard Digoxin Dosing | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Digoxin Dosing Per Nomogram | ||
| Total, all-cause mortality | Standard Digoxin Dosing | ||
| Total, other adverse events | Digoxin Dosing Per Nomogram | 0 | 65 |
| Total, other adverse events | Standard Digoxin Dosing | 0 | 66 |
| Total, serious adverse events | Digoxin Dosing Per Nomogram | 0 | 65 |
| Total, serious adverse events | Standard Digoxin Dosing | 0 | 66 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Digoxin Dosing Per Nomogram vs Standard Digoxin Dosing: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01005602
GET https://conductscience.org/api/trials/v1/NCT01005602/registered